

7th KOLKATA LIVER MEETING
6th, 7th and 8th Dec, 2018
Theme: Non-alcoholic Fatty Liver Disease

Thursday, 6th December, 2018

| | | | |
|----------------------|---------------------------------------------------------------------|----------------------------|-------------------|
| 13:00 - 14:00 | LUNCH | | |
| TIME | SESSIONS | DURATION (Mins) | SPEAKER |
| 14:00 - 15:50 | Session 1 :: NASH - The Disease | | |
| | NASH is a multi-systemic disease | 20 | Arun Sanyal |
| | NASH is all about Fibrosis: Clinical and economic implications | 20 | Zobair Younossi |
| | How do you identify the patient with "Progressive NASH" | 20 | Vlad Ratziu |
| | What is the Spectrum of Advanced NASH and HCC? | 20 | Jacob George |
| | NASH in India: Diversity and Distinctiveness | 20 | Abhijit Chowdhury |
| | Discussion | 10 | |
| 15:50 - 16:10 | COFFEE | | |
| 16:10 - 17:40 | Session 3: NASH - Pathology | | |
| | NASH - Histological characteristics and diagnosis | 20 | David Kleiner |
| | Can we correlate Histology with clinical Outcomes? | 20 | Rohit Loomba |
| | Is there a role for morphometry in liver histology? | 20 | David Kleiner |
| | Are we any closer to digital pathology aided with machine learning? | 20 | Arun Sanyal |
| | Discussion | 10 | |
| 17:40 - 18:50 | Session 2: NASH – Extra-hepatic Disease | | |
| | NASH and Extra-hepatic Cancer | 20 | Srijan Majumdar |
| | NASH and Diabetes - A Tale of Two cities and a Tunnel | 20 | V Mohan |
| | Cardiovascular Disease in NASH - Not just an Association | 20 | Jacob George |
| | Discussion | 10 | |
| 19:30 onwards | DINNER | | |

Friday 7th December, 2018

| TIME | SESSIONS | DURATION (Mins) | SPEAKER |
|---------------|------------------------------------------------------------------------------------------|-----------------|-------------------|
| 09:00 - 10:40 | Session 4 : NASH Evaluation - Clinical | | |
| | NASH Evaluation - An Overview | 20 | Laurent Castera |
| | MR Elastography and Management of NASH - Application | 20 | Richard Ehman |
| | MR PDFF in prediction of disease outcome and monitoring of therapy | 20 | Rohit Loomba |
| | Vibration controlled Transient Elastography in NASH management | 20 | Laurent Castera |
| | Available Serum Bio MARKERS in NASH : Are they Useful in clinical settings | 20 | Vlad Ratziu |
| 10:40 - 11:00 | Coffee break | | |
| 11:00 - 12:50 | Session 5: NASH Pathophysiology | | |
| | Is Insulin Resistance Central in NASH pathogenesis? | 20 | Gerald Shulman |
| | Mitochondrial dysfunction and altered Metabolic Flux in NASH | 20 | Kitt Petersen |
| | Lipotoxicity is a major Driver of NASH pathogenesis | 20 | Harmeet Mahi |
| | Inflammation in NASH : Cells , pathways , networks and Disease | 20 | Fabio Mara |
| | Putting the pieces in NASH pathogenesis together | 20 | Arun Sanyal |
| | Discussion | 10 | |
| 12:50 - 13:30 | A. K. Basu Memorial Oration | 40 | Scott Friedman |
| 13:30 - 14:30 | LUNCH | | |
| 14:30 - 15:50 | Session 6 : NASH - Clinical Decision making and Overlaps | | |
| | A case of NASH and management issues - multi organ and Multiple etiologies | 30 | Ajay Duseja |
| | NASH and ASH - The Two wings of a Fire so common | 20 | Ashwani Singhal |
| | NASH and Viral Hepatitis - natural History and therapy issues | 20 | Samir Shah |
| | Discussion | 10 | |
| 15:50 - 17:00 | Session 7 : NASH - Disease Modifiers and Implications | | |
| | Genetics and Epigenetics of NASH- can they influence patient management? | 20 | Julia Kotlizina |
| | Microbiome changes in NASH: cause or Effect | 20 | Lixin Jhu |
| | Integrating "Omics" Information in Drug Development | 20 | Mani Subramanian |
| | Discussion | 10 | |
| 17:00 - 17:20 | COFFEE BREAK | | |
| 17:20 - 18:30 | Session 8 : NASH - Across the Globe and lessons | | |
| | Screening for NASH in the General Population and Speciality Linkage - Spanish Experience | 20 | Jose Luis Calleja |
| | NASH in the Far East | 20 | Chan Wah Kheong |
| | Efforts to alter the NASH epidemic world wide - an integrated approach | 20 | Zobair Younossi |
| | Discussion | 10 | |
| 19:30 onwards | DINNER | | |

Saturday 8th December, 2018

| TIME | SESSIONS | DURATION (Mins) | SPEAKER |
|---------------|----------------------------------------------------------------------------------------------------------|-----------------|-----------------|
| 09:00 - 10:35 | Session 9 :: Navigating the Maze of Molecules in Clinical Trials | | |
| | Overview of the landscape: Compounds and End points | 25 | Rohit Loomba |
| | Targeting nuclear hormone modulators and metabolic enzymes | 20 | Vlad Ratziu |
| | Modulating inflammation and fibrosis | 20 | Scott Friedmann |
| | Mono-therapy or combination therapy for NASH? | 20 | Arun Sanyal |
| | Discussion | 10 | |
| 10:40 – 12:25 | Session 10 :: Complimentary approaches and addressing root cause of NASH | | |
| | Reversing insulin resistance: anti-diabetics and/or uncoupling? | 20 | Jerry Shulman |
| | Bariatric Surgery in NASH; Type of Surgery and mechanisms of improvement | 20 | Jacob George |
| | Role of modulating Inflammasome , TLRs and Ammonia in NASH | 20 | Rajiv Jalan |
| | Life Style Modifications in the era of pharmacotherapy | 15 | Akash Sukla |
| | How long will we have to treat NASH once effective pharmacotherapy is available - an outcome perspective | 20 | Zobair Younossi |
| | Discussion | 10 | |
| 12:25 - 12:45 | COFFEE | | |
| 12:45- 13:45 | Session 11: Future Perspective | | |
| | Basic research in in NASH and its' impact - the years Ahead | 20 | Scott Friedman |
| | Global initiatives on developing biomarkers | 20 | Arun sanyal |
| | How I evaluate and treat a patient with NASH today and How I will in 2020 | 20 | Rohit Loomba |
| 14:00 onwards | Lunch and Closure | | |